Scarica l'app Stockscreener
8.39
7.29%
0.57
Dopo l'orario di chiusura:
8.41
0.02
+0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.82
Aprire:
$8.21
Volume 24 ore:
30.48M
Relative Volume:
0.90
Capitalizzazione di mercato:
$8.63B
Reddito:
$113.29M
Utile/perdita netta:
$-351.47M
Rapporto P/E:
-21.52
EPS:
-0.3898
Flusso di cassa netto:
$-309.19M
1 W Prestazione:
-3.23%
1M Prestazione:
+41.13%
6M Prestazione:
+222.69%
1 anno Prestazione:
+189.31%
Intervallo 1D:
$8.20
$8.91
Intervallo di 1 settimana:
$7.77
$8.91
Portata 52W:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.39 | 8.63B | 113.29M | -351.47M | -309.19M | -0.3898 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | BTIG Research | Buy |
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Mostra tutto
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells’ - Insider Monkey
Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge - Yahoo Finance
ImmunityBio’s European Expansion Boosts Market Reach - timothysykes.com
IBRX Stock Rises 9%: ImmunityBio Reports Breakthrough In NK Cell Therapy Production - Stocktwits
ImmunityBio’s Market Expansion Amidst Financial Challenges - StocksToTrade
ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus - TechStock²
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking - Yahoo Finance
ImmunityBio Valuation: Paying 33x Sales for Anktiva - TradingView
IBRX Stock: Anktiva's Approvals and What Comes Next - TradingView
ImmunityBio updates on cell therapy programs (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio Expands Reach with European Approval, IBRX Stock Gains Momentum - timothysykes.com
ImmunityBio Shares Surge 295% Year-to-Date: Should You Buy, Hold, or Sell? - Bitget
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Investing News Network
Why ImmunityBio Stock Is Soaring Today - AOL.com
Why Is ImmunityBio Stock Soaring On Friday? - Benzinga
IMMUNITYBIO, INC. (IBRX) - MSN
ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell? - TradingView
ImmunityBio completes NK cell manufacturing programs - Investing.com
Single apheresis yields 5B NK cells in ImmunityBio cancer program - Stock Titan
Assessing ImmunityBio (IBRX) Valuation After FDA Acknowledges Resubmitted ANKTIVA Bladder Cancer Filing - Sahm
IBRX Stock: Anktiva Receives Approvals and Future Steps Ahead - Bitget
ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy - simplywall.st
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments - MarketBeat
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.2%What's Next? - MarketBeat
Immunitybio stock initiated at Buy by BTIG with $13 target - Investing.com
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets - Benzinga
IBRX Stock Rout Deepens: Founder Points To Cancer-Fighting Cell Bank Data As Investors Look For Catalyst - Stocktwits
IBRX Stock Declines — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Stocktwits
IBRX Stock Falls -23% In 6-Day Spree On Profit-Taking After 500% YTD Gain - Trefis
ImmunityBio Earnings Call: ANKTIVA Surge Amid High Burn - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio Faces Potential Setback Amid Director’s Share Sale and Investigation - timothysykes.com
ImmunityBio’s Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC) - marketscreener.com
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge - simplywall.st
FDA Review And Saudi Approval Keep ANKTIVA Central To ImmunityBio Story - Yahoo Finance
Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) - Bitget
IBRX stock declines — ImmunityBio resubmits Anktiva application to FDA with additional data - MSN
ImmunityBio (NASDAQ:IBRX) Shares Down 2.5%Should You Sell? - MarketBeat
ImmunityBio's (IBRX) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Can IBRX Stock Snap Its 4-Day Slide? Founder Promises ‘Game-Changer’ Anktiva Data As FDA Speeds Drug Reviews - Stocktwits
Behind the Scenes of ImmunityBio's Latest Options Trends - Benzinga
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Bitget
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - The Malaysian Reserve
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data - Asianet Newsable
ImmunityBio Stock Sinks as FDA Review Drags On - TipRanks
ImmunityBio resubmits bladder cancer application to FDA - Investing.com
ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG - TipRanks
FDA seeks more bladder cancer data; ImmunityBio resubmits ANKTIVA bid - Stock Titan
ImmunityBio’s Stock Sees a Huge Boost - Los Angeles Business Journal
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results - MSN
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):